Patent thickets extend market exclusivity, delaying generic competition and increasing drug costs, with $3.5 billion in excess spending identified for four drugs over two years. The study found that ...
Christian Meyer and Gisela Grabow of Maiwald explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster ...
The Commission opened proceedings against Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe B.V. in March 2021 under Article 102 TFEU, following dawn raids in October 2019; a ...
Remodulin and Adcirca have seen generic entry throughout 2018 and 2019, and we expect continued competition. Tyvaso and Orenitram will likely see generic entry in 2026 and 2027, respectively. While we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback